作者: Tracey Varker , Loretta Watson , Kari Gibson , David Forbes , Meaghan L. O’Donnell
DOI: 10.1080/02791072.2020.1817639
关键词:
摘要: The aim of this systematic review was to examine the efficacy MDMA, ketamine, LSD, and psilocybin for treatment posttraumatic stress disorder (PTSD). A search four databases English language, peer-reviewed literature published from inception 18th October 2019 yielded 2,959 records, 34 which were screened on full-text. Observational studies RCTs tested or reducing PTSD symptoms in adults, reported changes diagnosis symptomatology, included. Nine trials (five ketamine MDMA) met inclusion criteria. Trials rated a quality bias checklist GRADE used rank evidence. evidence as stand-alone comorbid depression ranked "very low", combination with psychotherapy "low". MDMA "moderate".